Literature DB >> 277246

Clinical studies with misonidazole.

C R Wiltshire, P Workman, J V Watson, N M Bleehen.   

Abstract

The preliminary details of a randomized clinical trial of misonidazole for the radiotherapy of Grades 3 and 4 cerebral astrocytoma are described. Plasma concentrations of misonidazole and its O-demethylated metabolite, determined by high-pressure liquid chromatography analysis, are reported for 8 patients with astrocytoma, 1 with carcinoma of the bronchus and 1 with carcinoma of the breast. In the latter case, tumour concentrations are also presented.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 277246      PMCID： PMC2149437     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN： 0306-9443


  9 in total

1.  Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo.

Authors:  J Denekamp; B D Michael; S R Harris
Journal:  Radiat Res       Date:  1974-10       Impact factor: 2.841

2.  Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles.

Authors:  J C Asquith; M E Watts; K Patel; C E Smithen; G E Adams
Journal:  Radiat Res       Date:  1974-10       Impact factor: 2.841

3.  Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells.

Authors:  R C Urtasun; J D Chapman; P Band; H R Rabin; C G Fryer; J Sturmwind
Journal:  Radiology       Date:  1975-10       Impact factor: 11.105

4.  Radiosensitizers of hypoxic cells in solid tumors.

Authors:  J F Fowler; G E Adams; J Denekamp
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

5.  Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors:  A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

6.  Radiation and high-dose metronidazole in supratentorial glioblastomas.

Authors:  R Urtasun; P Band; J D Chapman; M L Feldstein; B Mielke; C Fryer
Journal:  N Engl J Med       Date:  1976-06-17       Impact factor: 91.245

7.  Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours.

Authors:  R H Thomlinson; S Dische; A J Gray; L M Errington
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

8.  Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results.

Authors:  J L Foster; I R Flockhart; S Dische; A Gray; I Lenox-Smith; C E Smithen
Journal:  Br J Cancer       Date:  1975-06       Impact factor: 7.640

9.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640
  9 in total
  7 in total

1.  The penetration of misonidazole into spontaneous canine tumours.

Authors:  R A White; P Workman; L N Owen; N M Bleehen
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

2.  Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate.

Authors:  J S Mahood; R L Willson
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

3.  Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.

Authors:  J M Brown; N Y Yu; P Workman
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

4.  The penetration of misonidazole into a mature structural cartilage.

Authors:  A J Langler; R D Bugden; P Gibson
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

5.  Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.

Authors:  R A White; P Workman
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

6.  Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring.

Authors:  P Workman; C R Wiltshire; P N Plowman; N M Bleehen
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

7.  A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.

Authors:  N M Bleehen; C R Wiltshire; P N Plowman; J V Watson; J R Gleave; A E Holmes; W S Lewin; C S Treip; T D Hawkins
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.